莫西沙星结合亚胺培南治疗慢性阻塞性肺疾病并发感染性肺炎效果观察

Effect of moxifloxacin combined with imipenem in the treatment of chronic obstructive pulmonary disease complicated with infectious pneumonia

目的:观察莫西沙星结合亚胺培南治疗慢性阻塞性肺疾病并发感染性肺炎的效果;方法:选取2015年1月至2018年4月呼吸内科收治的94例慢性阻塞性肺疾病并发感染性肺炎患者,随机分成两组,对照组患者应用莫西沙星治疗,观察组患者应用莫西沙星结合亚胺培南治疗,比较两组患者临床疗效、病原菌清除率、治疗前后肺功能指标、临床症状消失时间及不良反应发生率。结果:观察组患者临床疗效总有效率为95.74%,病原菌清除率为93.55%,较对照组高,不良反应发生率低于对照组(P<0.05),治疗前两组患者MVV、FEV1.0指标水平差异无统计学意义(P>0.05),治疗后两组患者MVV、FEV1.0指标水平均提高,且观察组患者MVV、FEV1.0指标水平提高幅度更大(P<0.05),观察组患者体温恢复时间、湿啰音消失时间、白细胞计数正常时间、咳嗽消失时间低于对照组(P<0.05);结论:莫西沙星结合亚胺培南治疗慢性阻塞性肺疾病并发感染性肺炎可提高临床疗效、病原菌清除率,缩短临床症状改善时间,改善患者肺功能,且降低不良反应,建议在临床推广。

Objective: To observe the effect of moxifloxacin combined with imipenem in the treatment of chronic obstructive pulmonary disease complicated with infectious pneumonia. Methods: 94 cases of chronic obstructive pulmonary disease complicated with infectious pneumonia admitted from January 2015 to April 2018 were enrolled and divided into two groups. The control group was treated with moxifloxacin, and the observation group was given moxifloxacin combined with imipenem. The clinical efficacy, pathogen clearance rate, lung function index, clinical symptom disappearance time and adverse reaction rate between the two groups were compared. Results: In the observation group, the total effective rate was 95.74 % and the pathogen clearance rate was 93.55 %. The incidence of adverse reactions in the observation group was significantly lower than that of the control group and the difference was statistically significant ( P <0.05). There was no significant difference in the levels of MVV and FEV1.0 between the two groups before treatment ( P >0.05). After treatment, the MVV and FEV1.0 levels were significantly increased in the two groups, and the MVV and FEV1.0 levels in the observation group improved. Significantly, the differences were statistically significant ( P <0.05). The temperature recovery time, wet rales disappearance time, white blood cell count normal time, and cough disappearance time in the observation group were significantly lower than those in the control group, and the differences were statistically significant ( P < 0.05). Conclusion: Moxifloxacin combined with imipenem in the treatment of chronic obstructive pulmonary disease complicated with infectious pneumonia can significantly improve the clinical efficacy, pathogen clearance, shorten the clinical symptom improvement time, improve the lung function of patients, and reduce adverse reactions.